8-K: Iterum Therapeutics Announces FDA Acceptance of Oral Sulopenem NDA Resubmission and Nasdaq Compliance Extension

Iterum Therapeutics has received FDA acceptance for its oral sulopenem NDA resubmission with a PDUFA action date set for October 25, 2024, and has been granted a Nasdaq compliance extension until September 30, 2024.

Summary

• Iterum Therapeutics has entered into a consulting agreement with its former Chief Medical Officer, Dr. Sailaja Puttagunta, effective June 1, 2024, for $400 per hour to provide support during the regulatory review of the oral sulopenem NDA.
• The company received a 180-day extension from Nasdaq, until September 30, 2024, to regain compliance with listing rule 5550(b)(1) regarding minimum stockholders' equity.
• The FDA has accepted the resubmission of the New Drug Application (NDA) for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women.
• The FDA has assigned a PDUFA action date of October 25, 2024, for the oral sulopenem NDA, indicating a six-month review period.
• The resubmission includes data from the REASSURE clinical trial, which demonstrated that oral sulopenem was non-inferior to Augmentin and showed statistically significant superiority in overall success rate against Augmentin susceptible pathogens.

Sentiment

Score: 6

Explanation: The document contains both positive and negative elements. The FDA acceptance and positive trial data are encouraging, but the Nasdaq compliance issues and financial challenges temper the overall sentiment.

Positives

• The FDA's acceptance of the oral sulopenem NDA resubmission is a significant step towards potential approval.
• The PDUFA action date of October 25, 2024, provides a clear timeline for the regulatory review process.
• The REASSURE trial results support the efficacy of oral sulopenem, showing non-inferiority and statistically significant superiority over Augmentin.
• The Nasdaq extension provides additional time for Iterum to regain compliance with listing requirements.

Negatives

• Iterum was previously not in compliance with Nasdaq listing rule 5550(b)(1) due to a stockholders' equity deficit of ($6,403,000) as of December 31, 2023.
• There is no guarantee that Iterum will regain compliance with Nasdaq listing rules by September 30, 2024, and may face delisting.
• The company's ability to continue as a going concern is dependent on its cash resources and ability to maintain Nasdaq listing.

Risks

• Failure to regain compliance with Nasdaq listing rules by September 30, 2024, could lead to delisting.
• There is no assurance that the appeal of any delisting determination would be successful.
• The approval of oral sulopenem is not guaranteed, and the FDA may not approve the NDA.
• The company's financial position is precarious, with a significant stockholders' equity deficit.
• The company's future success is dependent on the outcome of the regulatory review and commercialization of oral sulopenem.

Future Outlook

The company is focused on working with the FDA during the review of the oral sulopenem NDA and regaining compliance with Nasdaq listing requirements. The company is also pursuing strategic alternatives, but there is no guarantee of success.

Management Comments

• Corey Fishman, Chief Executive Officer, stated that the FDA's acceptance of the NDA resubmission is a significant milestone and brings the company closer to potential approval of oral sulopenem.
• Corey Fishman also mentioned that oral sulopenem could provide patients and physicians with a much-needed treatment option for the underserved uUTI market.

Industry Context

The development of new antibiotics is crucial due to the increasing threat of multi-drug resistant pathogens. Iterum's oral sulopenem aims to address this need, particularly in the treatment of uncomplicated urinary tract infections, a common condition. The company is competing with other pharmaceutical companies developing new antibiotics, but the REASSURE trial results suggest a potential advantage over existing treatments like Augmentin.

Comparison to Industry Standards

• The REASSURE trial results, showing non-inferiority and statistically significant superiority of oral sulopenem over Augmentin, are a positive sign compared to the standard treatment for uUTIs.
• Companies like Nabriva Therapeutics and Paratek Pharmaceuticals are also developing new antibiotics, but Iterum's focus on oral sulopenem for uUTIs positions it uniquely in the market.
• The PDUFA action date of October 25, 2024, is a standard timeline for FDA review of a Class II complete response, aligning with industry norms.
• The Nasdaq compliance issue is not unique to Iterum, as many small biotech companies face challenges in maintaining listing requirements, but the extension provides a critical window for the company to address its financial issues.

Management Changes

Stakeholder Impact

• Shareholders are impacted by the Nasdaq compliance issues and the potential for delisting.
• Patients and physicians could benefit from the potential approval of oral sulopenem as a new treatment option.
• Employees are impacted by the company's financial situation and the uncertainty surrounding its future.

Next Steps

• Iterum will continue to work with the FDA during the review of the oral sulopenem NDA.
• The company will focus on regaining compliance with Nasdaq listing requirements by September 30, 2024.
• The company will continue to pursue strategic alternatives.

Key Dates

Keywords

sulopenem, FDA, NDA, PDUFA, Nasdaq, compliance, urinary tract infections, antibiotics, REASSURE trial, delisting